MedTrace Logo

Effects of Oral Sodium Bicarbonate Supplementation in Haemodialysis Patients (BicHD)

NCT02692378 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2016-10-03

No results posted yet for this study

Summary

The purpose of the study is to investigate whether oral sodium bicarbonate supplementation to ensure a constant bicarbonate profile in haemodialysis patients will primarily lower predialysis potassium levels and secondary lead to improvements in cardiac function, muscle mass and dialysis related symptoms.

Conditions

  • End-stage Renal Disease

Interventions

DRUG

sodium bicarbonate 500mg capsules

Defined by active substance and brand names not specified in protocol

Sponsors & Collaborators

  • National Institute for Health Research, United Kingdom

    collaborator OTHER_GOV

  • Imperial College Healthcare NHS Trust

    lead OTHER

Principal Investigators

  • Damien Ashby, PhD, MRCP · Imperial College Healthcare NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02692378 on ClinicalTrials.gov